IOVANCE BIOTHERAPEUTICS, INC. Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31)
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) of 0.87% for the 12-month period ending 2012-12-31, per its 10-K filed 2013-09-23.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssumptionsRiskFreeInterestRate · last filed 2013-09-23
- IOVANCE BIOTHERAPEUTICS, INC. fair value assumptions, risk free interest rate (deprecated 2018-01-31) for fiscal 2012 was 0.87%, a 89.13% increase from fiscal 2011.
- IOVANCE BIOTHERAPEUTICS, INC. fair value assumptions, risk free interest rate (deprecated 2018-01-31) for fiscal 2011 was 0.46%.
| Period end | Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 9 month | Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 12 month |
|---|---|---|
| 2012-12-31 | 0.87% 10-K · filed 2013-09-23 | |
| 2012-09-30 | 0.41% 10-Q · filed 2013-01-25 | |
| 2011-12-31 | 0.46% 10-K · filed 2013-09-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |